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Stage at diagnosis and colorectal cancer survival in six high-income countries: a population-
based study, 2000-2007  
Abstract 
Background: Large international differences in colorectal cancer survival exist, even between 
countries with similar healthcare. We investigate the extent to which stage at diagnosis explains these 
differences. 
Methods: Data from population-based cancer registries in Australia, Canada, Denmark, Norway, 
Sweden and the UK were analysed for 313,852 patients diagnosed with colon or rectal cancer during 
2000-7. We compared the distributions of stage at diagnosis. We estimated both stage-specific net 
survival and the excess hazard of death up to three years after diagnosis, using flexible parametric 
models on the log-cumulative excess hazard scale. 
Results: International differences in colon and rectal cancer stage distributions were wide: Denmark 
showed a distribution skewed towards later-stage disease, while Australia, Norway and the UK 
showed high proportions of ‘regional’ disease. One-year colon cancer survival was 67% in the UK 
and ranged between 71% (Denmark) and 80% (Australia and Sweden) elsewhere. For rectal cancer, 
one-year survival was also low in the UK (75%), compared to 79% in Denmark and 82-84% 
elsewhere. International survival differences were also evident for each stage of disease, with the UK 
showing consistently lowest survival at one and three years. 
Conclusion: Differences in stage at diagnosis partly explain international differences in colorectal 
cancer survival, with a more adverse stage distribution contributing to comparatively low survival in 
Denmark. Differences in stage distribution could arise because of differences in diagnostic delay and 
awareness of symptoms, or in the thoroughness of staging procedures. Nevertheless, survival 
differences also exist for each stage of disease, suggesting unequal access to optimal treatment, 
particularly in the UK. 
 
Keywords: colorectal cancer; survival; stage at diagnosis; population-based  
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Introduction 
Colorectal cancer is the third most common cancer and cause of cancer death worldwide.[1;2] There 
are large differences in survival globally,[3] between European countries [4;5] and between Europe 
and the US.[6] The International Cancer Benchmarking Partnership (ICBP) is a consortium of 
epidemiologists, clinicians and policy-makers seeking to explain colorectal cancer survival 
differences between six high-income countries with similar health systems. Predicted five-year 
survival was 12% higher in Australia than in the UK for patients diagnosed during 2005-7; survival 
was low in Denmark, intermediate in Norway, and high in Canada and Sweden.[7] Understanding the 
reasons behind these differences should help improve cancer control strategies.[8] We have reported 
the impact of stage at diagnosis, a crucial prognostic factor, on ovarian cancer survival.[9] Here, we 
consider whether stage at diagnosis could explain the international differences in overall colorectal 
survival in 2000-7, by comparing the distribution of stage at diagnosis in each country. Survival may 
also differ for each stage of disease: this would suggest differences in treatment, the quality of staging 
procedures, or levels of co-morbidity. 
 
We used population-based data from regional (Australia, Canada, Sweden, UK) and national 
(Denmark, Norway) cancer registries. In contrast to clinical trials, which routinely exclude older, 
more frail or marginalised patients, these data include all cancer patients in each region or country, 
thus enabling public health comparisons of the overall effectiveness of health systems. Stage at 
diagnosis is not routinely or consistently recorded by all cancer registries. Population-based studies of 
stage-specific survival have usually adopted a ‘high-resolution’ approach, in which investigators 
abstract detailed clinical data on stage directly from the medical records of large, random samples of 
patients derived from the cancer registry.[6;10;11] Here, we used data on stage held by the registries 
for all cancer patients in their territory. The data on stage were coded to a variety of classification 
systems. We therefore defined a repeatable process to consolidate these data into a common 
classification, in order to facilitate robust international comparisons of stage-specific survival[12]. We 
compared the distributions of stage at diagnosis in the six countries and overall and stage-specific 
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survival at one and three years after diagnosis. Using routine data on stage at diagnosis in 
international cancer survival comparisons should enable future cancer survival surveillance world-
wide. 
Material and Methods 
Data 
The International Cancer Benchmarking Partnership (ICBP) collected data on 788,311 patients 
diagnosed with colorectal cancer  during 1995-2007 in Australia (Victoria; New South Wales),  
Canada (Alberta, British Columbia, Manitoba, Ontario), Denmark, Norway, Sweden (Uppsala-Örebro 
and Stockholm-Gotland health regions), and the UK (England, Northern Ireland, Wales). Overall, 
these registries covered 80.5% of the combined population of these six countries: details have been 
published[7]. 
Data were cleaned and analysed centrally to a common protocol. We collected data on primary, 
invasive, malignant cancers of the colon (ICD-10 C18.0-C18.9), rectosigmoid junction (C19) and 
rectum (C20), but not cancers of the anus or anal canal (C21). We excluded patients whose tumour 
was benign (behaviour code 0), of uncertain behaviour (1) or in situ (2). Patients were excluded if 
their vital status was unknown or if their cancer was only registered from a death certificate. Full 
details of quality control have been published.[7] 
We restricted attention to the 468,258 patients diagnosed during 2000-7, when stage data were more 
complete. We excluded registries that had recorded stage data for less than 50% of patients in this 
period: thus Victoria (Australia), British Columbia and Ontario (Canada) and Wales (UK) were 
excluded from the analyses for colon cancer, while Victoria (Australia), Ontario (Canada), Thames 
(England, UK) and Wales (UK) were excluded from the analyses for rectal cancer. For Canada and 
Denmark, the availability of stage data increased markedly from 2004, following changes in policy, so 
we further excluded patients diagnosed during 2000-3 in those two countries. The final analyses 
included 208,281 colon cancer patients and 105,571 patients with rectal cancer. 
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The ICBP study protocol required both pathological and clinical T, N and M values, and/or Dukes’ 
stage where available. We defined a standard procedure[12] to determine which stage variables to use 
where the registry supplied more than one, prioritising individual T, N and M data over Dukes’ stage, 
and preferring pathological T and N over clinically-based values. The New South Wales registry uses 
a locally-specified coding system wherein tumours are classified as ‘localised, regional, distant’. 
Norway also uses its own coding system for colon cancer. Both systems could be translated to the US 
Surveillance, Epidemiology and End Results program’s Summary Stage 2000 (SEER SS2000); this is 
similar to the New South Wales system, but better documented and more widely known. By 
additionally mapping both TNM and Dukes’ systems to SEER SS2000, we were able to include all 
countries in comparative analyses. The analyses we present using SEER SS2000 therefore include all 
six countries; but where possible, we also present the results using the Dukes’ system, which is more 
familiar to clinicians.  
We present survival estimates for colon and rectal cancers separately, because they differ in stage 
distribution, treatment options and clinical behaviour. We consider three age groups: 15-49, 50-69 and 
70-99 years at diagnosis. For simplicity, we will use stages A-D when referring to Dukes' stage, and 
‘localised’, ‘regional’ or ‘distant’ when referring to SEER SS2000. 
Statistical analyses 
A major difficulty in international comparisons of cancer survival is that data on the cause of death 
may be incomplete, and death certification may not record cancer as the underlying cause of death 
with comparable accuracy between countries or over time.[14] Relative survival techniques have been 
used for many years to estimate net survival, which is the probability of survival for cancer patients in 
the hypothetical situation where cancer is the only cause of death. These techniques have recently 
been shown to incorporate bias in longer-term survival estimation due to “informative censoring.”[13] 
To estimate net survival by stage at diagnosis, age and country whilst avoiding this bias, we used 
flexible parametric excess hazard models on the log-cumulative excess hazard scale, implemented 
with the stpm2 command[15] in Stata version 12.0 (StataCorp LP, College Station, Texas). The 
Page 8 of 42
URL:http://mc.manuscriptcentral.com/SONC
Acta Oncologica
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
8 
 
expected risk of death (background mortality) by sex and single year of age at death was estimated 
from life tables specific to the population of each registry’s territory and each calendar year.[7] Net 
survival for a given group of patients is then the mean of the individual net survival probabilities 
predicted by the model at a given point in time since diagnosis. We also estimated the mortality 
counterpart of net survival, the excess hazard of death, which is the instantaneous risk of dying from 
cancer, over and above the expected risk of dying from all other causes, for up to three years after 
diagnosis. 
Stage-specific analyses were conducted with stage categorised either to Dukes’ or SEER SS2000. 
Patients with no data on stage were initially treated as a distinct category. Age was modelled as a 
continuous variable. We used polynomial functions (splines) to allow for the non-linear effects of 
time since diagnosis and the potentially non-linear effects of age on the excess hazard. We fitted 
interactions with time since diagnosis to allow for potentially non-proportional effects of age and 
country. The final models were selected using various measures of goodness of fit, including the 
Akaike Information Criterion (AIC) and the Schwarz Bayesian Information Criterion (BIC)[16]. We 
used a likelihood ratio test to test for the interaction between age and country, allowing a 20% 
probability of type I error. Final models were compared with slightly more flexible models to reveal 
any excessive constraints, such as proportional effects or lack of flexibility, but the survival estimates 
were not changed by this increased flexibility. We examined plots of the Martingale residuals to 
ensure correct specification of the functional form used to model the effect of age. In order to assess 
the validity of our final models, we also modelled the data from each country separately, and obtained 
very similar results; therefore, we present only the results from the final models that include country. 
The availability of follow-up data beyond the last boundary for which we want to estimate survival is 
important for the stability of the model, so we present survival estimates up to three years, even 
though we had longer follow-up for some patients.[17] 
To determine the probable stage for patients with missing data we performed multiple imputation by 
chained equations, using the ice command[18] in Stata 12. For each country in turn, we specified an 
ordered logistic regression model including vital status, the non-linear effect of the log-cumulative 
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excess hazard, and the non-linear effect of age, as well as all covariables that significantly predicted 
stage for patients in that country with known stage, or that predicted the absence of stage (potentially: 
sub-site, sex, year of diagnosis and any interactions between these covariables and the excess 
hazard).[19;20] We ran the imputation procedure 15 times on each data set and combined the results 
under Rubin’s rules.[21] 
We used the same modelling strategy to estimate stage-specific net survival in each of the 15 imputed 
datasets and compared the range of estimates to the survival estimates obtained for patients for whom 
stage had been reported in the original data. 
For each category of stage, all-ages survival estimates were standardised with weights derived from 
the distribution of patients in the age categories 15-44, 45-54, 55-64, 65-74, 75-84 and 85-99 years in 
all jurisdictions combined (web appendix, Tables 1 and 2). 
Differences between paired survival estimates, and overall ranges, are given as the simple arithmetic 
value, e.g. 12% would be 2% (and not 20%) higher than 10%.  Survival estimates are rounded to 
integer values in the text, but differences and ranges are based on the exact underlying values. The 
statistical significance of differences in survival was assessed at the 5% level on the basis of the 
excess hazard ratios derived from the models; we present 95% confidence intervals for most 
estimates. 
Results 
Stage and age distributions 
The proportion of patients for whom data on stage at diagnosis were missing was highest in the UK 
(colon: 27.8%; rectum: 30.6%) and lowest in Sweden for colon cancer (3.4%) and Norway for rectal 
cancer (7.1%) (Table 1). The proportion increased with age (web appendix Figure 1). For colon 
cancer, the mean age at diagnosis was slightly higher in Norway and Sweden (72.6 years) than in 
Canada or Australia (70.5 years), while for rectal cancer the range was from 67.7 years (Australia) to 
70.6 years (Sweden) (Table 1). 
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Insert Table 1 
Insert Figure 1 
Imputation of stage where it was missing did not substantially alter the stage distributions, either for 
colon or rectal cancer.  
Colon cancer was more commonly diagnosed at an early stage (A) in Canada, at intermediate stages 
(B and C) in Sweden and the UK, and at an advanced stage (D) in Denmark (Table 1). The proportion 
with advanced disease was low in the UK (20% vs. 24-31% elsewhere), but the proportion in stage C 
was high (36% vs. 26-29% elsewhere). The distribution of stage in SEER SS2000 varied more widely: 
the proportion of patients with ‘regional’ disease was 54% in Norway and 46% in Australia, but 30-
37% elsewhere. In Denmark, 31% of patients had ‘distant’ disease, compared with 19-27% in the 
other five countries.  
The stage distributions for rectal cancer were similar in Canada, Norway and Sweden, for both Dukes’ 
and SEER SS2000 categorisations. The distribution was more heavily skewed towards later stage in 
Denmark than in other countries, again with both classifications. The proportion of patients diagnosed 
in stage D was lower in the UK (19%) and Australia (17%) than elsewhere (23-29%), and the 
proportion in stage C was much higher (35%), whereas these proportions were more similar in other 
countries. The proportion of patients with ‘regional’ tumours ranged from 40-42% in Australia and 
Denmark to 30-36% elsewhere.  
Net survival 
Overall, one-year age-standardised net survival from colon cancer was lowest in the UK (67.4%), 
followed by Denmark (71.3%) (Table 2). Survival was intermediate in Norway (75.5%) and Canada 
(76.2%) and highest in Sweden (79.9%) and Australia (80.2%). Similarly, survival from rectal cancer 
was lowest in the UK (75.2%) and Denmark (79.0%), intermediate in Norway (82.3%) and highest in 
Canada (84.0%), Sweden (84.4%) and Australia (83.6%) (Table 3). For both colon and rectal cancers, 
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the same patterns of survival by country were found three years after diagnosis (web appendix, Tables 
3 and 4). 
Insert Table 2 and Table 3 
One-year net survival from both colon and rectal cancer was statistically significantly lower for each 
age group in the UK than in all other countries (except compared to the youngest age group in 
Denmark), and the differences were widest for patients aged 70-99 years (5-15%, Tables 2 and 3). For 
both cancers, the largest between-country difference in one-year net survival was twice as wide for 
70-99 year-olds as it was for 15-49 year-olds. 
International differences in age-standardised net survival at one year were wider for patients with 
more advanced stage of disease at diagnosis. Thus in the UK, survival for colon cancer patients with 
stage A disease was similar to that in other countries, but up to 5% lower than elsewhere for stage B, 
while the deficits with respect to Denmark, Canada and Sweden for more advanced stages of disease 
were large and statistically significant (7-11% for stage C and 5-8% for stage D) (Table 2). The 
Dukes’ stage-specific age-standardised one-year net survival estimates were also low in Denmark, but 
the differences with other countries were not generally statistically significant. A similar pattern of 
wider international differences for patients with more advanced disease was also observed with SEER 
SS2000 stage (Table 2) and three years after diagnosis in both stage classifications (web appendix 
Table 3). 
For rectal cancer, international differences in net survival at one and three years were also wider for 
patients with more advanced stage at diagnosis (Table 3; web appendix Table 4). Age-standardised 
one-year net survival for ‘localised’ disease was up to 5% lower in the UK than elsewhere, but 7-14% 
lower for patients with ‘distant’ disease (Table 3). 
Among patients for whom SEER SS2000 stage data were not available, the international range in one-
year net survival was as wide as 30% for colon cancer and 21% for rectal cancer, with the lowest 
values in the UK and the highest in Australia (Tables 2 and 3). The international range in survival was 
also wide among patients for whom Dukes’ stage was not available. For colon cancer, survival for 
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patients missing SEER SS2000 in Canada was low, as was survival among rectal cancer patients with 
missing stage in Sweden. 
Excess hazard  
The excess hazard of death at one month after diagnosis was approximately 10 times higher for 
patients with advanced disease than those with early-stage disease (Figures 1 and 2). There was a 
noticeable decrease in the excess hazard of death between one and six months after diagnosis, 
particularly for patients diagnosed at an early stage. As a result, the difference in the excess hazard of 
death between early and advanced disease widened to almost 100-fold by 3 years after diagnosis. This 
pattern was observed for both colon and rectal cancer, and in each country.  
For each stage at diagnosis, international differences in the excess hazard of death diminished with 
time since diagnosis. An exception was seen for patients with stage A colon cancer, where the excess 
hazard in Sweden declined continuously with time, resulting in a particularly low excess hazard 3 
years after diagnosis. 
For colon cancer, the excess hazard of death was relatively stable from 6 months to 3 years after 
diagnosis, in each country and within each stage category.  
Insert Figures 2 and 3   
For rectal cancer, the excess hazard of death at one month was similar for stage B and C (Figure 2) in 
all countries except Sweden. From six months onwards, the excess hazard of death was higher for 
patients in each successive category of stage at diagnosis. 
Net survival following imputation 
After imputation of stage where it was missing from the original record, net survival estimates were 
generally similar to, or lower than, the estimates for patients with known stage, for both colon and 
rectal cancer. The only exception was survival for patients with stage D in Norway. However, the 
international range in stage-specific survival became wider (Figures 3 and 4). Imputation had an 
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especially large effect on one-year net survival in the UK, where the estimates were reduced by as 
much as 15.5% for stage C colon cancer and 9.6% for stage C rectal cancer. Similar findings were 
observed at three years (web appendix, Figures 2 and 3). 
Insert Figures 4 and 5 
Discussion 
Cancer survival varied widely between these six countries. For colon cancer, age-standardised one-
year net survival was highest in Australia and Sweden, intermediate in Canada and Norway, lower in 
Denmark and lowest in the UK, with a range of 13%. For rectal cancer, survival was lowest in the 
UK, intermediate in Denmark and Norway, and highest in Australia, Canada and Sweden, with a 
range of 9%. These international differences in survival are partly explained by differences in the 
distribution of stage at diagnosis. For each stage at diagnosis, however, international variation in 
survival was also wide, particularly for patients with more advanced disease. 
Before considering the implications of these findings, we describe how we have addressed three 
aspects of data quality: the lack of comparability between the various classifications of stage at 
diagnosis, differences in clinical staging procedures, and incompleteness of data on stage.  
Data on stage were provided in four different classifications. We developed an algorithm to translate 
these to a common standard before survival analysis[12]. For a few categories of stage, a small degree 
of misclassification was unavoidable. For example, in mapping Dukes’ stage to SEER Summary 
Stage 2000, it is unavoidable that about 2-3% of colorectal patients are misclassified as ‘localised’ 
rather than ‘regional’, because it is not possible to distinguish between T3 and T4 among tumours 
assigned to Dukes’ B if the component T, N and M codes are not available. This may partly explain 
why Australia and Norway have higher proportions of patients with ‘regional’ tumours. Incomplete 
documentation on the categories of stage used for colon cancer in Norway may have increased this 
type of misclassification and contributed to the unusual stage distribution. 
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The thoroughness of clinical investigation to determine the stage at diagnosis may also differ between 
countries. This can affect the observed distribution of stage, and both stage-specific and overall 
survival. For example, it is possible that sub-optimal staging in the UK (leading to misclassification of 
some Dukes’ stage D tumours as stage C) explains both the particularly low proportion of metastatic 
tumours (Dukes’ D), and the unusually high proportion of Dukes’ C. This may be why patients in 
both stage categories had substantially lower survival than elsewhere (stage migration[22]). Sub-
optimal staging of colorectal cancer in England has been identified in an international study of clinical 
records, which showed that fewer lymph nodes were examined pathologically than elsewhere in 
Europe, and liver imaging was performed less often.[10] More accurate staging would be expected to 
result in treatment that is more appropriate for stage, and thus higher survival. Concern about the 
consistency of staging quality in England has also been noted by a parliamentary committee.[8] 
Cancer registries should routinely record the investigations that were performed to ascertain the stage 
at diagnosis (as has been done in Sweden since 2007). At the very least, registries should record 
whether stage was defined before or after histological investigation. This would improve 
comparability in international studies of stage at diagnosis and stage-specific survival.  
We restricted the inclusion of data in these analyses to registries in which at least 50% of all patients 
were staged, in order to improve the generalisability of the results. In these data sets, stage was 
missing for 3-31% of patients. We imputed stage where it was missing, in order to reduce potential 
bias in stage-specific survival. Imputation is the most robust method for dealing with missing data, 
even when there are few variables with which to predict the missing values.[20] Patients with missing 
data on stage tended to be older, and to have lower survival, which is why survival is lower in all 
stage categories after the inclusion of patients whose stage data were imputed.  
Standard methods were used to deal with other issues of comparability and consistency that affect any 
population-based comparisons of cancer survival. Potential confounding by age was handled by age-
standardisation. Consistent exclusion criteria were applied to cancer registrations from all countries 
and quality control was conducted centrally according to a common protocol. The completeness of 
registration of incident cancers is high in all these registries, but small differences could still 
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contribute to differences in survival. In Sweden, cancer registrations are not initiated from death 
certificates, as elsewhere: some patients with poor survival could be missed as a result, but the 
completeness of the Swedish data is very high,[23] and the effect on overall survival will be 
minimal.[24] A more serious issue for the survival comparisons was that sufficient information on 
stage was only available in the Canadian registries and Denmark for patients diagnosed during 2004-
7, compared to 2000-7 in the other jurisdictions. Since survival was improving over time,[7] we 
would expect this to confer a slight advantage to Canada and Denmark in the survival comparisons, 
but a comparison of one-year survival for patients diagnosed during 2004-7 in all jurisdictions did not 
change the international pattern of survival reported here (results available on request). 
International differences in clinical staging procedures and data comparability may contribute 
marginally to international differences in stage distribution and survival, but they cannot fully explain 
the large international inequalities in survival and the pattern of those inequalities by stage. The stage 
distributions that we describe using these routinely collected cancer registry data are consistent with 
those found previously in population-based studies in the same countries.[25-28] The survival 
estimates are clinically coherent in terms of age, stage and time since diagnosis, and they echo 
previous findings where available.[10;29;30] Particularly high excess mortality at one month after 
diagnosis has also been reported before.[31-33] The observation that older patients generally have a 
more favourable stage distribution than younger patients, even after the imputation of missing stage,is  
also consistent with previous studies.[34-36] Therefore, while it is important that consistency in 
staging is improved for future population-based studies of colorectal cancer survival, this study shows 
overwhelming evidence of survival inequalities by stage of disease, as well as in the stage 
distribution. Both inequalities require policy attention. 
During 2000-7, no country had implemented a national screening programme using the faecal occult 
blood test (FOBT), but most were running pilot programmes in selected regions, for example in 
Odense (Denmark), since 1985 and in Nottingham (UK), since 1981. Gradual implementation of a 
national FOBT screening programme began in England from mid-2006, but the impact on national 
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distributions of stage and overall survival during the overall period 2000-7 is likely to have been 
small.[37] 
Age-standardised one-year net survival ranged by 13% between the UK and Australia for colon 
cancer and by 9% between the UK and Sweden for rectal cancer, and patients in the UK consistently 
had the lowest survival at one and three years. The difference between the UK and the other five 
countries was statistically significant for each age group, except compared to the youngest age group 
in Denmark. The low survival in the UK cannot be fully explained by a more adverse stage 
distribution; survival in the UK was significantly lower than elsewhere for Dukes’ stage C and D 
cancers and survival was also statistically significantly lower for each category of SEER SS2000, 
except for the comparison with ‘localised’ rectal cancer in Denmark. We have alluded to the possible 
contribution of sub-optimal staging, but problems with access to optimal treatment may also 
contribute to the low survival in the UK. 
Improvement in colorectal cancer survival has been attributed to three main factors: rising resection 
rates, falling post-operative mortality and the increased use of adjuvant chemotherapy.[27;38] 
Variation in these factors may help to explain international differences in stage-specific survival, 
particularly the low survival observed in the UK. EUROCARE data from the early 1990s have shown 
that resection rates in the UK were lower than in other European countries,[10] and post-operative 
mortality in the UK remains relatively high.[28] Current treatment guidelines are similar in the 
UK[39] and in countries with higher stage-specific survival like Canada,[40] but research is needed 
on their implementation. 
In Denmark, age-standardised one-year net survival for colon cancer was statistically significantly 
lower by 4-9% than in the other countries except the UK, and 3-6% lower for rectal cancer. Stage-
specific survival was also often slightly lower than elsewhere, but not consistently, and differences 
were only statistically significant for one-year survival from colon cancer. Denmark had the most 
adverse stage distribution for both colon and rectal cancer. A more advanced stage distribution has 
Page 17 of 42
URL:http://mc.manuscriptcentral.com/SONC
Acta Oncologica
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
17 
 
been noted previously in Denmark for colorectal cancer[41] and other cancers.[42] The reorganisation 
of cancer services in Denmark, which began in 2007, may improve this situation.[43] 
Age-specific one-year net survival was higher for colon cancer in Australia and Sweden than 
elsewhere, and for rectal cancer in Canada and Sweden. Sweden and Canada had an unremarkable 
stage distribution, but high stage-specific survival, suggesting that other countries should aim for the 
stage-specific outcomes achieved in those countries. 
In conclusion, there are wide international inequalities in survival from colorectal cancer, even 
between economically developed countries. Stage at diagnosis is crucial to prognosis. International 
surveillance of cancer survival by stage would be greatly improved by global consensus on a single 
cancer staging classification, and by consistent recording in cancer registries of stage at diagnosis and 
the procedures used to determine it. 
Stage at diagnosis is an important contributing factor to low overall survival in Denmark. Elsewhere, 
the international differences in overall survival are also reflected within each category of stage, and 
this is more likely to be attributable to differences in the quality of staging and treatment. The UK in 
particular should consider its performance in this regard. 
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Figure titles and legends 
Figure 1. Age-standardised excess hazard of death (per 1,000 person-years, log scale) from colon 
cancer, by stage, country and time since diagnosis: Dukes' stage (upper graphic) and SEER Summary 
Stage 2000 (lower graphic) 
Notes 
1. National data are used for Denmark and Norway. Other countries are represented by regional 
registries: Australia: New South Wales; Canada: Alberta and Manitoba; Sweden: Uppsala-Örebro and 
Stockholm-Gotland health regions; UK: England and Northern Ireland. In Canada and Denmark we 
analysed data for patients diagnosed in 2004-7 
2. For each country, the size of the “bubble” represents the proportion of cancers in each stage at 
diagnosis (see legend at bottom right of graphic). The relative size of the bubbles is therefore the same 
at each time since diagnosis. 
Figure 2. Age-standardised excess hazard of death (per 1,000 person-years, log scale) from rectal 
cancer, by stage, country and time since diagnosis: Dukes' stage (upper graphic) and SEER Summary 
Stage 2000 (lower graphic) 
Notes 
1. National data are used for Denmark and Norway. Other countries are represented by regional 
registries: Australia: New South Wales; Canada: Alberta, British Columbia and Manitoba; Sweden: 
Uppsala-Örebro and Stockholm-Gotland health regions; UK: Northern Ireland and all cancer 
registries in England except the Thames Cancer Registry. In Canada and Denmark we analysed data 
for patients diagnosed in 2004-7 
2. For each country, the size of the “bubble” represents the proportion of cancers in each stage at 
diagnosis (see legend at bottom right of graphic). The relative size of the bubbles is therefore the same 
at each time since diagnosis. 
Figure 3. Colon cancer: age-standardised one-year net survival for patients diagnosed 2000-7, by 
stage at diagnosis and country, Dukes’ stage (A: upper graphic) and SEER Summary Stage 2000 (B: 
lower graphic) 
X - survival estimate derived from those patients for whom the stage was recorded at diagnosis 
I - range of survival estimates for all patients, both those with known stage and those for whom it was 
imputed, derived from 15 data sets after imputation (see text for details) 
 
Notes: 
National data are used for Denmark and Norway. Other countries are represented by regional 
registries: Australia: New South Wales; Canada: Alberta and Manitoba; Sweden: Uppsala-Örebro and 
Stockholm-Gotland health regions; UK: England and Northern Ireland. In Canada and Denmark, data 
are for patients diagnosed in 2004-7 
 
Figure 4. Rectal cancer: age-standardised one-year net survival for patients diagnosed 2000-7, by 
stage at diagnosis and country, Dukes’ stage (A: upper graphic) and SEER Summary Stage 2000 (B: 
lower graphic) 
X - survival estimate derived from those patients for whom the stage was recorded at diagnosis 
I - range of survival estimates for all patients, both those with known stage and those for whom it was 
imputed, derived from 15 data sets after imputation (see text for details) 
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24 
 
Notes: 
National data are used for Denmark and Norway. Other countries are represented by regional 
registries: Australia: New South Wales; Canada: Alberta, British Columbia and Manitoba; Sweden: 
Uppsala-Örebro and Stockholm-Gotland health regions; UK: Northern Ireland and all cancer 
registries in England except the Thames Cancer Registry. In Canada and Denmark, data are for 
patients diagnosed in 2004-7 
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 Table 1. Number and mean age at diagnosis of colon and rectal cancer patients diagnosed during 2000-2007: country and stage at diagnosis (Dukes' stage and SEER Summary Stage 2000) 
 
 Dukes' stage SEER Summary Stage 2000 
 Colon Rectum Colon Rectum 
 % % % % 
 
Stage Number6 
Mean 
age Observed 
After 
imputation Number6 
Mean 
age Observed 
After 
imputation Stage Number6 
Mean 
age Observed 
After 
imputation Number6 
Mean 
age 
Observe
d 
After 
imputation 
 
A
u
s
t
r
a
l
i
a
1
 
 
All patients 22,197 70.7 11,748 67.7 
 Missing 
stage 1,875 72.3 8.4 1,303 69.0 11.1 
 Localised 7,117 71.0 35.0 34.8 4,316 68.4 41.3 41.2 
 Regional 9,328 70.5 45.9 45.9 4,365 67.1 41.8 41.8 
 Distant 3,877 69.7 19.1 19.4 1,764 66.3 16.9 17.0 
 
 
C
a
n
a
d
a
2
,
5
 
All patients 5,784 70.5 6,405 67.8 All patients 5,784 70.5 6,405 67.8 
 Missing 
stage 364 73.4 6.3 1,633 70.4 25.5 
Missing 
stage 364 73.4 6.3 1,633 70.4 25.5 
 A 951 70.8 17.5 17.3 1,050 68.3 22.0 21.2 Localised 2,305 71.3 42.5 41.9 1,983 68.4 41.6 40.4 
 B 1,654 71.4 30.5 30.2 1,108 68.4 23.2 22.3 Regional 1,707 70.2 31.5 31.5 1,678 65.9 35.2 34.9 
 C 1,407 70.2 26.0 26.0 1,503 65.7 31.5 31.8 Distant 1,408 68.9 26.0 26.5 1,111 65.6 23.3 24.7 
 D 1,408 68.9 26.0 26.5 1,111 65.6 23.3 24.8 
 
 
D
e
n
m
a
r
k
5
 
All patients 10,057 71.8 5,744 69.3 All patients 10,057 71.8 5,744 69.3 
 Missing 
stage 2,007 75.5 20.0 1,338 73.5 23.3 
Missing 
stage 2,007 75.5 20.0 1,338 73.5 23.3 
 A 891 71.4 11.1 11.0 590 69.5 13.4 13.2 Localised 2,933 71.9 36.4 36.2 1,483 69.1 33.7 33.3 
 B 2,450 72.2 30.4 30.2 1,061 68.8 24.1 23.7 Regional 2,617 70.5 32.5 32.5 1,775 66.8 40.3 40.1 
 C 2,209 70.1 27.4 27.4 1,607 66.7 36.5 36.5 Distant 2,500 70.3 31.1 31.3 1,148 68.3 26.1 26.5 
 D 2,500 70.3 31.1 31.4 1,148 68.3 26.1 26.6 
 
 
N
o
r
w
a
y
 
All patients 8,756 70.4 All patients 17,450 72.6 8,756 70.4 
 
Missing 
stage 2,627 71.4 30.0 
Missing 
stage 1,348 76.0 7.7 625 75.4 7.1 
 
A 1,528 70.6 24.9 21.6 Localised 3,117 73.0 19.4 19.2 3,875 70.8 47.7 46.9 
 
B 1,684 71.0 27.5 24.9 Regional 8,779 72.7 54.5 54.4 2,480 69.5 30.5 30.8 
 
C 1,540 69.1 25.1 24.9 Distant 4,206 70.9 26.1 26.4 1,776 69.0 21.8 22.3 
 
D 1,377 69.0 22.5 28.6 
 
 
S
w
e
d
e
n
3
 
All patients 10,653 72.6 5,519 70.6 All patients 10,653 72.6 5,519 70.6 
 Missing 
stage 361 77.2 3.4 541 78.6 9.8 
Missing 
stage 361 77.2 3.4 541 78.6 9.8 
 A 1,178 72.8 11.4 11.4 1,153 70.2 23.2 22.4 Localised 4,852 73.5 47.1 46.8 2,449 70.4 49.2 47.9 
 B 3,788 73.8 36.8 36.6 1,330 70.5 26.7 26.0 Regional 3,043 72.1 29.6 29.7 1,462 69.3 29.4 29.5 
 C 2,929 72.0 28.5 28.6 1,428 69.3 28.7 28.7 Distant 2,397 70.7 23.3 23.5 1,067 68.7 21.4 22.6 
 D 2,397 70.7 23.3 23.5 1,067 68.7 21.4 22.9 
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1 Australia: New South Wales 
2 Canada (Colon): Alberta and Manitoba; Canada (Rectum): Alberta, British Columbia and Manitoba 
3 Sweden: Uppsala-Örebro and Stockholm-Gotland health regions 
4 United Kingdom (Colon): Northern Ireland and all cancer registries in England; United Kingdom (Rectum): Northern Ireland and all cancer 
registries in England except the Thames Cancer Registry 
5 In Canada and Denmark we analysed patients diagnosed in 2004-7 
6 Number of patients before imputation 
 
U
K
4
 
All patients 142,140 72.3 67,399 70.4 All patients 142,140 72.3 67,399 70.4 
 Missing 
stage 39,585 74.8 27.8 20,630 73.3 30.6 
Missing 
stage 39,585 74.8 27.8 20,630 73.3 30.6 
 A 9,644 71.2 9.4 8.4 9,693 69.5 20.7 19.1 Localised 48,299 72.2 47.1 43.2 22,796 69.9 48.7 45.5 
 B 39,588 72.4 38.6 35.7 13,355 70.1 28.6 26.9 Regional 36,970 70.7 36.0 37.3 16,054 68.2 34.3 35.5 
 C 36,037 70.7 35.1 36.4 15,802 68.2 33.8 34.9 Distant 17,286 70.6 16.9 19.6 7,919 68.9 16.9 19.0 
 D 17,286 70.6 16.9 19.5 7,919 68.9 16.9 19.2 
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Table 2. All-ages, age-specific and age-standardised one-year net survival (%) by stage at diagnosis and country for colon cancer patients diagnosed during 2000-2007 
Australia1 Canada2,5 Denmark5 Norway Sweden3 UK4 
NS (%) 95% CI NS (%) 95% CI NS (%) 95% CI NS (%) 95% CI NS (%) 95% CI NS (%) 95% CI 
Dukes' stage 
                    All patients All ages 76.9 75.8 78.1 71.8 70.9 72.8 79.8 79.0 80.6 67.3 67.1 67.6 
Age-standardised  76.2 75.4 77.1 71.3 70.6 72.1 79.9 79.3 80.5 67.4 67.2 67.6 
15-49 85.6 83.3 87.9 82.8 80.3 85.4 85.7 83.7 87.6 80.6 79.9 81.4 
50-69 83.0 81.6 84.3 79.8 78.6 80.9 83.6 82.6 84.6 76.5 76.1 76.8 
70-99 72.0 70.5 73.6 66.3 65.0 67.5 77.5 76.5 78.5 61.6 61.3 61.9 
 
Dukes' stage A All ages 95.4 93.8 97.1 92.3 90.1 94.5 97.4 96.1 98.7 95.8 95.2 96.3 
Age-standardised 95.4 94.1 96.8 92.3 90.6 94.0 97.8 97.0 98.7 95.7 95.3 96.2 
15-49 99.0 97.0 100.0 99.5 98.4 100.0 99.8 99.1 100.0 98.8 98.0 99.6 
50-69 
 
98.2 96.9 99.6 97.2 95.5 98.8 
 
99.0 97.7 100.0 97.8 97.3 98.3 
70-99 93.2 90.4 95.9 88.9 85.6 92.3 96.5 94.7 98.3 94.4 93.5 95.2 
 
Dukes' stage B All ages 92.9 91.5 94.3 91.2 89.8 92.5 94.9 94.0 95.8 90.1 89.8 90.5 
Age-standardised 92.7 91.9 93.6 91.0 90.2 91.8 95.1 94.7 95.6 90.1 89.8 90.4 
15-49 97.7 97.1 98.3 97.1 96.4 97.8 98.5 98.1 98.9 96.8 96.2 97.4 
50-69 96.1 95.3 97.0 94.8 94.0 95.7 97.3 96.8 97.8 94.4 94.0 94.7 
70-99 90.7 88.8 92.6 88.7 87.0 90.5 93.7 92.6 94.8 87.6 87.1 88.0 
 
Dukes' stage C All ages 87.4 85.6 89.2 84.0 82.3 85.6 86.2 85.0 87.5 76.8 76.4 77.2 
Age-standardised 
    
87.6 86.3 88.9 83.4 82.1 84.7 
    
86.9 86.1 87.7 76.8 76.4 77.1 
15-49 95.3 93.0 97.5 95.7 93.3 98.0 94.1 92.4 95.8 87.2 86.0 88.3 
50-69 94.0 92.4 95.5 89.5 87.8 91.2 91.7 90.5 92.8 83.6 83.1 84.1 
70-99 
     
82.1 79.4 84.9 78.6 76.1 81.1 
   
82.5 80.7 84.2 71.4 70.8 72.0 
 
Dukes' stage D All ages 41.0 38.6 43.4 41.0 39.1 42.9 41.8 40.0 43.6 34.1 33.4 34.7 
Age-standardised 39.3 37.6 41.0 40.6 39.3 42.0 42.1 40.8 43.4 34.2 33.7 34.7 
15-49 63.5 57.8 69.2 58.3 52.7 64.0 56.5 51.0 62.0 50.8 48.4 53.2 
50-69 52.2 48.7 55.7 51.2 48.5 53.9 52.1 49.5 54.8 43.6 42.6 44.7 
70-99 28.5 25.5 31.5 31.6 29.3 34.0 33.2 30.9 35.5 26.0 25.2 26.8 
 
                       Missing stage All ages 60.4 55.6 65.2 64.0 61.9 66.2 63.3 58.3 68.3 43.0 42.5 43.4 
Age-standardised 59.0 55.0 62.9 64.5 62.8 66.2 65.7 61.7 69.6 42.9 42.6 43.3 
15-49 89.6 82.3 96.9 88.8 82.4 95.1 96.1 85.9 100.0 72.4 70.6 74.1 
50-69 77.9 71.2 84.5 80.4 77.6 83.3 83.8 77.8 89.9 58.9 58.1 59.7 
70-99 49.0 42.7 55.3 57.1 54.4 59.8 56.6 50.5 62.6 35.3 34.7 35.8 
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1 Australia: New South Wales 
2 Canada: Alberta and Manitoba 
3 Sweden: Uppsala-Örebro and Stockholm-Gotland health regions 
4 United Kingdom: Northern Ireland and all cancer registries in England 
5 In Canada and Denmark we analysed patients diagnosed in 2004-7 
 
 
 
SEER Summary Stage 2000 
 
All patients All ages 81.0 80.4 81.5 76.9 75.8 78.1 71.9 70.9 72.8 75.1 74.5 75.8 79.8 79.0 80.6 67.4 67.1 67.6 
Age-standardised 80.2 79.8 80.6 76.3 75.4 77.2 71.5 70.7 72.2 75.5 75.0 76.0 79.9 79.4 80.5 67.5 67.3 67.7 
15-49 88.9 87.8 90.0 85.6 83.3 87.9 82.8 80.3 85.4 84.4 82.9 86.0 85.6 83.7 87.5 80.6 79.8 81.3 
50-69 86.0 85.4 86.6 83.0 81.6 84.3 79.7 78.6 80.9 81.6 80.8 82.5 83.6 82.6 84.6 76.5 76.1 76.8 
70-99 76.8 76.0 77.5 72.1 70.5 73.6 66.3 65.1 67.6 71.3 70.4 72.1 77.5 76.5 78.5 61.6 61.3 62.0 
 
Localised All ages 94.9 94.3 95.6 95.1 94.0 96.2 92.7 91.6 93.9 93.3 92.2 94.4 95.5 94.8 96.3 91.3 91.0 91.6 
Age-standardised 94.7 94.1 95.2 95.0 94.1 95.8 92.5 91.6 93.5 93.7 92.9 94.5 95.8 95.3 96.3 91.3 91.1 91.5 
15-49 99.1 98.7 99.5 99.1 98.2 100.0 98.5 97.3 99.8 99.0 98.2 99.7 99.4 99.0 99.9 97.3 96.8 97.8 
50-69 97.7 97.2 98.2 97.9 97.1 98.8 96.7 95.7 97.7 97.8 97.0 98.5 97.8 97.2 98.4 95.1 94.8 95.4 
70-99 92.8 91.7 93.8 93.1 91.5 94.8 90.0 88.3 91.8 90.9 89.3 92.4 94.4 93.3 95.4 88.9 88.5 89.4 
 
Regional All ages 87.1 86.4 87.8 86.5 84.8 88.2 83.5 82.0 85.1 87.7 86.9 88.4 86.2 85.0 87.5 77.1 76.7 77.5 
Age-standardised 86.9 86.4 87.5 86.6 85.4 87.8 83.0 81.8 84.2 88.5 88.0 89.0 86.8 86.0 87.7 76.9 76.5 77.2 
15-49 94.6 93.6 95.6 95.1 93.1 97.2 95.7 93.4 97.9 95.5 94.5 96.5 94.3 92.7 95.9 87.7 86.6 88.7 
50-69 91.2 90.5 91.8 93.3 91.7 94.8 89.3 87.7 90.9 93.2 92.5 93.9 91.8 90.7 92.9 84.0 83.5 84.5 
70-99 83.6 82.6 84.7 81.0 78.5 83.6 78.2 75.9 80.5 84.5 83.5 85.5 82.5 80.8 84.2 71.7 71.0 72.3 
 
Distant All ages 42.6 41.1 44.1 41.1 38.7 43.5 41.1 39.2 43.0 38.5 37.1 39.9 41.9 40.0 43.7 34.1 33.5 34.8 
Age-standardised 42.0 40.9 43.0 39.5 37.8 41.2 40.7 39.4 42.1 39.0 38.0 40.0 42.1 40.8 43.5 34.2 33.7 34.7 
15-49 61.9 57.9 65.9 63.3 57.6 69.0 58.1 52.5 63.8 56.2 51.9 60.4 56.4 50.9 61.8 50.5 48.1 52.8 
50-69 53.2 51.1 55.3 52.4 48.9 55.9 51.4 48.7 54.0 49.8 47.7 51.8 52.4 49.8 55.0 43.8 42.8 44.8 
70-99 32.2 30.3 34.0 28.6 25.6 31.6 31.7 29.4 34.1 29.6 28.0 31.3 33.2 30.9 35.4 26.0 25.2 26.8 
 
Missing stage All ages 76.2 74.3 78.2 49.4 43.9 55.0 64.2 62.0 66.4 65.4 62.9 67.9 63.5 58.5 68.5 43.4 42.9 43.8 
Age-standardised 73.7 72.0 75.4 48.6 44.2 53.1 64.7 63.0 66.4 67.3 65.4 69.1 65.9 62.0 69.8 43.4 43.0 43.8 
15-49 93.0 90.0 96.0 86.7 77.5 95.8 88.9 82.6 95.2 90.5 84.9 96.0 96.1 85.9 100.0 72.7 70.9 74.4 
50-69 87.8 85.9 89.7 63.8 53.9 73.8 80.4 77.6 83.3 85.5 82.5 88.5 83.9 77.9 89.9 59.1 58.3 59.9 
70-99 68.3 65.6 71.0 40.1 33.4 46.8 57.3 54.7 60.0 57.6 54.5 60.7 56.8 50.7 62.8 35.7 35.2 36.2 
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Table 3. All-ages, age-specific and age-standardised one-year net survival (%) by stage at diagnosis and country for rectal cancer patients diagnosed during 2000-2007 
   
Australia1 
 
Canada2,5 
 
Denmark5 
 
Norway 
 
Sweden3 
 
UK4 
NS (%) 95% CI NS (%) 95% CI NS (%) 95% CI NS (%) 95% CI NS (%) 95% CI NS (%) 95% CI 
Dukes' stage 
                         All patients All ages 84.8 83.9 85.7 79.6 78.5 80.7 81.8 80.9 82.6 84.1 83.1 85.1 74.9 74.6 75.2 
Age-standardised 84.0 83.3 84.7 79.0 78.2 79.9 82.3 81.7 82.8 84.4 83.7 85.1 75.2 75.0 75.5 
15-49 91.6 90.1 93.0 88.5 86.0 91.0 90.8 89.3 92.2 89.5 87.4 91.6 86.0 85.2 86.9 
50-69 89.2 88.2 90.1 87.3 86.2 88.4 88.0 87.2 88.9 89.2 88.2 90.1 83.2 82.8 83.6 
70-99 79.2 77.8 80.7 71.6 69.8 73.3 76.3 75.1 77.5 79.9 78.4 81.3 67.7 67.2 68.2 
 Dukes' stage A All ages 97.1 96.0 98.3 96.0 93.8 98.1 97.4 96.5 98.4 98.8 97.8 99.9 95.7 95.1 96.2 
Age-standardised 97.1 96.4 97.7 96.0 94.8 97.1 97.6 97.1 98.1 98.9 98.3 99.4 95.7 95.4 96.0 
15-49 99.4 99.1 99.7 99.2 98.7 99.7 99.5 99.3 99.8 99.8 99.6 100.0 99.2 98.9 99.4 
50-69 98.4 97.7 99.1 97.7 96.4 99.0 98.6 98.1 99.2 99.4 98.8 99.9 97.5 97.1 97.9 
70-99 95.6 93.8 97.4 94.1 90.9 97.2 96.4 95.0 97.7 98.4 96.9 99.9 93.8 93.0 94.6 
 Dukes' stage B All ages 94.3 93.0 95.7 92.3 90.6 94.0 92.8 91.6 94.1 97.7 96.6 98.8 91.4 90.9 91.9 
Age-standardised 
 
94.1 93.2 95.0 91.8 90.6 93.0 93.5 92.8 94.2 97.8 97.2 98.3 91.5 91.1 91.8 
15-49 99.3 98.9 99.8 98.8 98.0 99.6 99.3 99.0 99.6 99.0 98.4 99.6 98.1 97.8 98.5 
50-69 97.4 96.6 98.3 95.9 94.7 97.2 97.2 96.6 97.9 98.3 97.6 99.0 95.0 94.5 95.4 
70-99 
     
90.5 87.9 93.0 88.2 85.2 91.1 89.4 87.4 91.4 97.1 95.6 98.7 88.2 87.4 89.0 
 Dukes' stage C All ages 93.3 91.9 94.6 90.8 89.3 92.3 90.9 89.4 92.4 93.8 92.3 95.3 87.3 86.8 87.9 
Age-standardised 92.7 91.6 93.7 90.0 88.7 91.2 91.5 90.5 92.4 94.2 93.3 95.0 87.4 87.0 87.8 
15-49 97.4 96.0 98.7 95.7 93.3 98.0 97.6 96.5 98.7 98.4 97.5 99.4 94.5 93.4 95.5 
50-69 95.7 94.5 96.8 94.9 93.7 96.2 95.1 94.1 96.2 97.0 96.1 97.8 92.1 91.6 92.6 
70-99 89.3 86.8 91.8 84.7 81.8 87.6 86.5 84.1 89.0 90.5 88.2 92.9 81.7 80.8 82.6 
 Dukes' stage D All ages 58.9 56.1 61.7 52.3 49.4 55.2 49.7 47.3 52.1 51.9 49.1 54.7 42.6 41.5 43.6 
Age-standardised 56.9 55.4 58.4 52.2 50.8 53.7 50.6 49.3 51.8 52.4 51.0 53.8 43.2 42.5 43.8 
15-49 69.9 66.9 72.8 66.0 62.8 69.2 64.7 61.7 67.7 65.8 62.4 69.2 57.9 55.2 60.7 
50-69 66.0 63.3 68.6 61.0 58.3 63.8 60.1 57.7 62.4 61.4 58.7 64.1 52.5 51.2 53.8 
70-99 46.4 43.0 49.8 41.4 38.2 44.7 38.9 36.3 41.6 41.2 38.1 44.3 31.7 30.4 32.9 
 Missing stage All ages 
     
79.8 77.8 81.8 72.7 70.2 75.2 76.6 74.8 78.3 56.3 52.0 60.7 57.1 56.4 57.8 
Age-standardised 79.8 78.3 81.3 75.1 73.3 76.9 77.4 76.1 78.6 61.3 58.0 64.7 59.4 58.9 59.9 
15-49 92.4 89.2 95.7 92.9 87.9 97.9 92.3 88.9 95.6 68.5 44.8 92.1 79.4 77.3 81.4 
50-69 88.7 86.6 90.8 86.5 83.8 89.2 87.9 86.0 89.8 73.2 66.3 80.1 70.1 69.2 71.1 
70-99 71.7 68.7 74.7 64.4 60.9 67.8 67.6 65.0 70.1 52.1 47.2 56.9 49.0 48.1 49.8 
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SEER Summary Stage 2000  
All patients All ages 84.6 84.0 85.3 84.3 83.5 85.2 79.1 78.1 80.2 81.7 80.9 82.5 84.0 83.0 85.0 75.1 74.8 75.4 
Age-standardised 83.6 83.1 84.2 83.5 82.8 84.2 78.6 77.7 79.4 82.2 81.6 82.8 84.3 83.6 85.0 75.4 75.2 75.7 
15-49 90.3 89.2 91.5 91.3 89.8 92.8 88.3 85.7 90.8 90.7 89.2 92.2 89.4 87.3 91.5 86.2 85.4 87.0 
50-69 89.0 88.4 89.7 88.8 87.9 89.8 87.0 85.9 88.1 88.0 87.2 88.9 89.1 88.2 90.1 83.5 83.1 83.8 
70-99 79.2 78.1 80.3 78.6 77.1 80.0 70.9 69.2 72.6 76.2 75.0 77.4 79.7 78.3 81.2 67.9 67.4 68.4 
                     Localised All ages 94.1 93.4 94.8 96.5 95.6 97.4 94.4 93.0 95.7 94.3 93.6 95.1 98.3 97.5 99.1 93.2 92.9 93.6 
Age-standardised 93.9 93.4 94.3 96.4 95.8 97.0 94.1 93.2 95.1 94.9 94.5 95.4 98.4 97.9 98.8 93.3 93.0 93.5 
15-49 99.2 98.9 99.5 99.7 99.5 99.9 99.4 98.9 99.9 99.5 99.3 99.7 99.3 98.9 99.7 98.6 98.4 98.9 
50-69 97.1 96.6 97.6 98.6 98.1 99.2 97.4 96.5 98.4 97.9 97.5 98.3 98.8 98.2 99.3 96.1 95.8 96.4 
70-99 90.6 89.3 91.9 94.0 92.3 95.7 91.0 88.6 93.4 91.4 90.1 92.8 97.9 96.8 99.0 90.5 89.9 91.1 
 Regional All ages 91.2 90.3 92.0 92.6 91.4 93.9 90.0 88.5 91.5 89.9 88.6 91.2 93.8 92.3 95.3 87.3 86.8 87.8 
Age-standardised 91.0 90.4 91.6 92.1 91.1 93.1 89.2 88.0 90.4 90.7 89.9 91.5 94.2 93.4 95.1 87.4 87.0 87.7 
15-49 95.8 94.8 96.9 97.1 95.8 98.4 95.2 92.8 97.7 97.2 96.0 98.4 98.4 97.4 99.4 94.4 93.4 95.4 
50-69 94.8 94.1 95.4 95.3 94.2 96.4 94.4 93.1 95.6 95.1 94.2 95.9 97.0 96.2 97.9 92.1 91.6 92.6 
70-99 86.4 84.8 87.9 88.3 86.0 90.7 83.6 80.8 86.4 84.9 82.8 86.9 90.5 88.2 92.9 81.6 80.7 82.5 
 Distant All ages 52.1 49.9 54.3 58.9 56.1 61.8 52.3 49.4 55.2 49.3 47.1 51.5 51.9 49.2 54.7 42.6 41.6 43.6 
Age-standardised 50.9 49.7 52.1 57.0 55.5 58.4 52.4 50.9 53.8 50.4 49.2 51.5 52.5 51.1 54.0 43.3 42.7 44.0 
15-49 64.6 61.7 67.5 70.2 67.4 73.0 66.4 63.3 69.5 64.7 62.0 67.4 66.2 63.0 69.4 58.4 55.9 60.9 
50-69 60.2 58.0 62.3 66.0 63.4 68.6 61.1 58.3 63.8 59.7 57.5 61.8 61.4 58.8 64.1 52.6 51.3 53.8 
70-99 
 
39.5 37.0 42.1 46.3 42.9 49.6 41.4 38.1 44.6 38.2 35.8 40.7 41.1 38.0 44.2 31.6 30.4 32.8 
 Missing stage All ages 81.0 78.8 83.2 79.0 77.0 81.0 72.7 70.1 75.2 61.2 57.4 65.0 56.3 52.0 60.6 57.1 56.4 57.7 
Age-standardised 79.5 77.8 81.2 78.7 77.1 80.2 74.6 72.7 76.4 68.6 65.9 71.3 60.9 57.6 64.2 58.8 58.3 59.3 
15-49 94.2 91.6 96.9 92.0 88.6 95.4 92.9 87.9 97.9 91.1 83.3 98.9 68.4 44.7 92.1 79.2 77.2 81.3 
50-69 89.1 86.9 91.2 88.0 85.8 90.2 86.4 83.8 89.1 86.6 82.0 91.1 73.1 66.2 80.0 70.1 69.1 71.0 
70-99 72.2 68.9 75.6 70.8 67.7 73.9 64.3 60.9 67.8 49.3 44.5 54.1 52.1 47.2 56.9 49.0 48.1 49.8 
1 Australia: New South Wales 
2 Canada: Alberta, British Columbia and Manitoba 
3 Sweden: Uppsala-Örebro and Stockholm-Gotland health regions 
4 United Kingdom: Northern Ireland and all cancer registries in England except the Thames Cancer Registry 
5 In Canada and Denmark we analysed patients diagnosed in 2004-7 
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Figure 1. Age-standardised excess hazard of death (per 1,000 person-years, log scale) from colon cancer by stage, country and 
time since diagnosis: Dukes' stage (upper figure) and SEER Summary Stage 2000 (lower figure)
Notes
1. National data are used for Denmark and Norway. Other countries are represented by regional registries: Australia: New South Wales; 
Canada: Alberta and Manitoba; Sweden: Uppsala-Örebro and Stockholm-Gotland health regions; UK: England and Northern Ireland. In 
Canada and Denmark we analysed patients diagnosed in 2004-7
2. For each country, the size of the “bubble” represents the proportion of cancers in each stage at diagnosis (see legend at bottom right of 
figure). The relative size of the bubbles is therefore the same at each time since diagnosis.
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Figure 2. Age-standardised excess hazard of death (per 1,000 person-years, log scale) from rectal cancer by stage, country and time 
since diagnosis: Dukes' stage (upper figure) and SEER Summary Stage 2000 (lower figure)
Notes
1. National data are used for Denmark and Norway. Other countries are represented by regional registries: Australia: New South Wales; Canada: 
Alberta, British Columbia and Manitoba; Sweden: Uppsala-Örebro and Stockholm-Gotland health regions; UK: Northern Ireland and all cancer 
registries in England except the Thames Cancer Registry. In Canada and Denmark we analysed patients diagnosed in 2004-7
2. For each country, the size of the “bubble” represents the proportion of cancers in each stage at diagnosis (see legend at bottom right of 
figure). The relative size of the bubbles is therefore the same at each time since diagnosis.
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A- Dukes' stage
Figure 3. Age-standardised one-year net survival from colon cancer by stage at 
diagnosis and country using known stage and imputed stage, Dukes' (upper figure) and 
SEER Summary Stage 2000 (lower figure)
B- SEER Summary Stage 2000
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where it was missing (see text)
Notes:
National data are used for Denmark and Norway. Other countries are represented by regional 
registries: Australia: New South Wales; Canada: Alberta and Manitoba; Sweden: Uppsala-
Örebro and Stockholm-Gotland health regions; UK: England and Northern Ireland. In Canada 
and Denmark we analysed patients diagnosed in 2004-7
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A- Dukes' stage
Figure 4. Age-standardised one-year net survival from rectal cancer by stage at 
diagnosis and country using known stage and imputed stage, Dukes' (upper figure) 
and SEER Summary Stage 2000 (lower figure)
B- SEER Summary Stage 2000
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National data are used for Denmark and Norway. Other countries are represented by regional 
registries: Australia: New South Wales; Canada: Alberta, British Columbia and Manitoba; 
Sweden: Uppsala-Örebro and Stockholm-Gotland health regions; UK: Northern Ireland and 
all cancer registries in England except the Thames Cancer Registry. In Canada and Denmark 
we analysed patients diagnosed in 2004-7
survival estimate derived from patients with known stage
range of survival estimates derived for all patients after imputation of stage 
where it was missing (see text)
40
60
80
10
0
O
ne
-y
ea
r n
et
 s
ur
vi
va
l (
%
)
Page 35 of 42
URL:http://mc.manuscriptcentral.com/SONC
Acta Oncologica
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
Stage at diagnosis and colorectal cancer survival in six high-income countries: a population-
based study, 2000-7  
 
WEB APPENDIX 
Web appendix table 1 Stage-specific sets of weights used for age standardisation of colon cancer 
estimates 
Web appendix table 2 Stage-specific sets of weights used for age standardisation of rectal cancer 
estimates  
Web appendix figure 1 Proportions of colon cancer patients with missing data on stage (upper 
figure) and cumulative stage distribution (lower figure) by age at diagnosis and country, Dukes' (left) 
and SEER Summary Stage 2000 (right) 
Web appendix table 3 All-ages, age-specific and age-standardised three-year net survival (%) by 
stage at diagnosis, age and country for colon cancer patients diagnosed during 2000-2007 
Web appendix table 4 All-ages, age-specific and age-standardised three-year net survival (%) by 
stage at diagnosis, age and country for rectal cancer patients diagnosed during 2000-2007 
Web appendix figure 2 Age-standardised three-year net survival from colon cancer by stage at 
diagnosis and country using known stage and imputed stage, Dukes' (upper figure) and SEER 
Summary Stage 2000 (lower figure) 
Web appendix figure 3 Age-standardised three-year net survival from rectal cancer by stage at 
diagnosis and country using known stage and imputed stage, Dukes' (upper figure) and SEER 
Summary Stage 2000 (lower figure) 
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Dukes' stage Age
category Weights
SEER Summary Stage 2000 Age
category Weights
15-44 0.03 15-44 0.03
45-54 0.06 45-54 0.06
55-64 0.16 55-64 0.17
65-74 0.29 65-74 0.29
75-84 0.34 75-84 0.33
85-99 0.13 85-99 0.12
15-44 0.02 15-44 0.02
45-54 0.06 45-54 0.06
55-64 0.17 55-64 0.16
65-74 0.32 65-74 0.30
75-84 0.34 75-84 0.36
85-99 0.08 85-99 0.10
15-44 0.02 15-44 0.03
45-54 0.05 45-54 0.07
55-64 0.15 55-64 0.18
65-74 0.30 65-74 0.30
75-84 0.36 75-84 0.32
85-99 0.11 85-99 0.10
15-44 0.03 15-44 0.03
45-54 0.07 45-54 0.08
55-64 0.19 55-64 0.19
65 74 0 31 65 74 0 29
Dukes' stage C Distant
Dukes' stage B Regional
Web appendix table 1. Stage-specific sets of weights used for age standardisation of colon 
cancer estimates
All patients All patients
Dukes' stage A Localised
- . - .
75-84 0.32 75-84 0.30
85-99 0.09 85-99 0.10
15-44 0.03 15-44 0.03
45-54 0.08 45-54 0.05
55-64 0.19 55-64 0.13
65-74 0.30 65-74 0.24
75-84 0.30 75-84 0.35
85-99 0.10 85-99 0.21
15-44 0.03
45-54 0.05
55-64 0.13
65-74 0.24
75-84 0.35
85-99 0.21
Dukes' stage D Missing stage
Missing stage
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Dukes' stage Age
category Weights
SEER Summary Stage 2000 Age
category Weights
15-44 0.03 15-44 0.03
45-54 0.08 45-54 0.09
55-64 0.21 55-64 0.21
65-74 0.30 65-74 0.30
75-84 0.28 75-84 0.28
85-99 0.09 85-99 0.09
15-44 0.03 15-44 0.02
45-54 0.08 45-54 0.08
55-64 0.22 55-64 0.22
65-74 0.33 65-74 0.32
75-84 0.28 75-84 0.28
85-99 0.07 85-99 0.07
15-44 0.02 15-44 0.03
45-54 0.08 45-54 0.10
55-64 0.21 55-64 0.24
65-74 0.32 65-74 0.31
75-84 0.30 75-84 0.26
85-99 0.07 85-99 0.05
15-44 0.03 15-44 0.04
45-54 0.10 45-54 0.11
55-64 0.24 55-64 0.23
65 74 0 32 65 74 0 30
Dukes' stage C Distant
Dukes' stage B Regional
Web appendix table 2. Stage-specific sets of weights used for age standardisation of rectal 
cancer estimates
All patients All patients
Dukes' stage A Localised
- . - .
75-84 0.26 75-84 0.26
85-99 0.05 85-99 0.07
15-44 0.03 15-44 0.02
45-54 0.10 45-54 0.07
55-64 0.23 55-64 0.16
65-74 0.30 65-74 0.25
75-84 0.26 75-84 0.31
85-99 0.07 85-99 0.18
15-44 0.02
45-54 0.07
55-64 0.17
65-74 0.25
75-84 0.31
85-99 0.18
Dukes' stage D Missing stage
Missing stage
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A- COLON
B- RECTUM
Web appendix figure 1. Proportions of colon cancer patients with missing data on stage (upper figure) and cumulative stage distribution (lower figure) by age 
at diagnosis and country, Dukes' (left) and SEER Summary Stage 2000 (right)
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Notes
National data are used for Denmark and Norway. Other countries are represented by regional registries: Australia: New South Wales; Canada (Colon): Alberta and 
Manitoba; Canada (Rectum): Alberta, British Columbia and Manitoba; Sweden: Uppsala-Örebro and Stockholm-Gotland health regions; UK (Colon): England and Northern 
Ireland; UK (Rectum): Northern Ireland and all cancer registries in England except the Thames Cancer Registry. In Canada and Denmark we analysed patients diagnosed 
in 2004-7
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NS (%) NS (%) NS (%) NS (%) NS (%) NS (%)
All ages 62.8 61.1 64.5 58.1 56.8 59.5 68.1 67.1 69.1 54.9 54.6 55.2
Age-standardised 62.2 61.0 63.4 57.7 56.7 58.7 68.2 67.4 69.0 54.9 54.7 55.1
15-49 70.0 65.8 74.2 66.9 62.5 71.2 71.0 67.6 74.4 65.1 64.1 66.1
50-69 67.9 65.7 70.1 64.9 63.1 66.7 70.1 68.7 71.6 62.0 61.6 62.5
70-99 58.6 56.4 60.8 53.4 51.7 55.1 66.9 65.5 68.2 50.4 50.0 50.7
All ages 94.0 91.0 97.1 88.8 84.8 92.7 98.2 96.7 99.8 94.9 94.1 95.7
Age-standardised 94.0 91.9 96.1 88.7 85.8 91.6 98.4 97.5 99.3 94.9 94.2 95.5
15-49 96.7 90.5 100.0 98.2 94.5 100.0 99.7 98.4 100.0 96.7 95.1 98.3
50-69 96.1 93.4 98.8 93.1 89.4 96.8 98.7 96.7 100.0 95.9 95.1 96.7
70-99 92.4 87.8 97.0 85.6 79.8 91.4 97.9 96.2 99.7 94.2 92.9 95.4
All ages 87.3 84.7 89.9 87.0 84.6 89.3 91.3 90.0 92.6 84.8 84.3 85.3
Age-standardised 87.1 85.7 88.5 86.8 85.6 88.1 91.5 90.8 92.2 84.8 84.4 85.2
15-49 91.7 89.7 93.7 91.5 89.7 93.4 94.6 93.6 95.7 90.1 88.9 91.4
50-69 90.1 88.1 92.2 89.6 87.7 91.5 93.5 92.4 94.5 88.1 87.5 88.6
70-99 85.3 82.4 88.3 85.2 82.5 87.8 90.3 88.8 91.8 82.8 82.1 83.5
All ages 70.5 67.2 73.9 67.2 64.3 70.0 68.7 66.7 70.7 58.2 57.6 58.8
Age-standardised 70.7 68.2 73.2 66.5 64.4 68.7 69.6 68.1 71.0 58.1 57.7 58.6
15-49 81.8 74.1 89.5 86.1 78.8 93.3 78.7 73.5 84.0 65.8 63.9 67.7
50-69 81.0 76.9 85.2 73.4 69.9 77.0 76.0 73.5 78.5 64.4 63.6 65.2
70-99 62.2 57.5 67.0 60.5 56.4 64.5 63.8 61.0 66.5 53.4 52.6 54.2
All ages 12.9 10.7 15.2 12.9 11.1 14.7 15.6 14.1 17.2 11.6 11.1 12.1
Age-standardised 11.9 10.6 13.2 12.8 11.6 13.9 15.7 14.7 16.8 11.6 11.3 12.0
15-49 26.3 19.2 33.3 21.2 15.4 27.1 21.8 16.4 27.2 18.3 16.3 20.3
50-69 18.4 14.9 21.9 18.1 15.4 20.8 21.4 18.9 23.9 16.0 15.1 16.8
70-99 6.4 4.6 8.3 8.2 6.5 10.0 11.1 9.4 12.8 8.0 7.4 8.5
All ages 47.3 41.1 53.5 56.3 53.4 59.3 50.7 44.4 56.9 31.3 30.8 31.8
Age-standardised 45.8 41.1 50.5 56.8 54.7 59.0 53.6 48.8 58.4 31.2 30.8 31.6
15-49 81.9 69.8 94.0 83.1 73.7 92.4 92.9 74.5 100.0 58.2 56.2 60.2
50-69 66.2 57.0 75.4 73.4 69.6 77.3 74.8 66.2 83.5 44.8 43.9 45.7
70-99 34.5 26.9 42.2 49.1 45.6 52.7 42.7 35.3 50.1 24.6 24.0 25.1
All ages 69.9 69.2 70.6 62.8 61.1 64.5 58.1 56.8 59.5 63.0 62.1 63.8 68.1 67.1 69.1 54.9 54.6 55.2
Age-standardised 69.2 68.7 69.8 62.3 61.0 63.5 57.8 56.8 58.8 63.2 62.6 63.9 68.2 67.4 69.0 55.0 54.8 55.2
15-49 77.2 75.3 79.2 70.0 65.8 74.2 66.9 62.5 71.2 69.8 67.2 72.5 71.0 67.5 74.4 65.0 64.1 66.0
50-69 74.4 73.5 75.3 67.8 65.6 70.1 64.8 63.1 66.6 67.9 66.7 69.1 70.1 68.6 71.5 62.0 61.5 62.4
70-99 66.2 65.2 67.2 58.7 56.5 60.9 53.5 51.7 55.2 60.0 58.9 61.1 66.9 65.5 68.3 50.4 50.0 50.8
All ages 92 5 91 5 93 4 91 9 89 9 93 8 89 6 87 5 91 7 90 9 89 4 92 5 92 8 91 7 93 9 87 0 86 6 87 5
Missing stage
SEER Summary Stage 2000
All patients
Localised
Dukes' stage D
95% CI 95% CI 95% CI 95% CI
Dukes' stage
All patients
Dukes' stage A
Dukes' stage B
Dukes' stage C
95% CI 95% CI
Web appendix table 3. All-ages, age-specific and age-standardised three-year net survival (%) by stage at diagnosis, age and country for colon cancer patients diagnosed during 2000-2007
Australia1 Canada2,5 Denmark5 Norway Sweden3 UK4
 . . . . . . . . . . . . . . . . . .
Age-standardised 92.2 91.5 92.9 91.6 90.2 93.1 89.4 87.9 90.9 91.3 90.2 92.4 93.0 92.2 93.8 87.0 86.7 87.4
15-49 97.1 95.7 98.5 96.6 93.2 99.9 95.5 91.5 99.4 96.7 94.2 99.2 97.9 96.4 99.5 91.5 90.4 92.6
50-69 95.0 94.1 95.9 94.8 92.9 96.8 93.3 91.3 95.2 95.4 94.0 96.8 94.8 93.6 96.0 89.9 89.4 90.4
70-99 90.4 89.0 91.8 89.7 86.8 92.5 87.1 84.1 90.0 88.5 86.3 90.7 91.7 90.2 93.2 85.3 84.7 85.9
All ages 74.7 73.6 75.7 70.4 67.4 73.5 67.6 64.9 70.3 77.2 76.1 78.3 68.8 66.8 70.7 58.5 58.0 59.1
Age-standardised 74.5 73.7 75.3 70.4 68.2 72.7 67.1 65.1 69.1 78.1 77.3 78.9 69.5 68.1 71.0 58.4 57.9 58.8
15-49 83.5 80.8 86.3 82.0 75.2 88.7 86.1 79.3 93.0 86.1 83.3 89.0 78.8 73.6 84.1 65.9 64.0 67.7
50-69 78.6 77.3 79.9 80.0 76.2 83.9 73.8 70.5 77.1 83.5 82.1 84.9 76.0 73.5 78.5 64.6 63.8 65.4
70-99 71.2 69.6 72.7 62.7 58.4 67.0 61.4 57.7 65.1 73.6 72.1 75.2 64.0 61.3 66.7 53.9 53.1 54.7
All ages 20.1 18.7 21.4 12.9 10.6 15.1 12.9 11.0 14.7 14.2 13.1 15.3 15.7 14.1 17.3 11.6 11.1 12.1
Age-standardised 19.6 18.7 20.6 11.9 10.6 13.2 12.8 11.6 13.9 14.4 13.6 15.2 15.8 14.7 16.9 11.7 11.3 12.0
15-49 32.8 28.1 37.4 26.4 19.4 33.5 21.3 15.4 27.2 22.9 18.8 27.1 22.1 16.7 27.5 18.5 16.5 20.6
50-69 26.2 24.2 28.3 18.0 14.6 21.5 17.7 15.0 20.4 19.8 18.0 21.6 21.1 18.7 23.6 15.7 14.9 16.6
70-99 13.8 12.3 15.3 6.5 4.6 8.4 8.4 6.7 10.2 9.7 8.6 10.9 11.3 9.6 13.0 8.2 7.6 8.7
All ages 64.2 61.9 66.6 32.3 25.4 39.1 56.0 53.0 59.0 56.7 53.7 59.7 50.6 44.4 56.9 31.3 30.8 31.8
Age-standardised 61.0 59.0 63.0 31.3 26.4 36.2 56.6 54.5 58.8 58.8 56.6 61.0 53.6 48.9 58.4 31.3 30.9 31.7
15-49 86.4 80.9 92.0 75.6 59.9 91.3 83.0 73.6 92.4 84.7 76.0 93.3 92.9 74.5 100.0 58.3 56.3 60.2
50-69 79.0 76.1 81.9 44.9 32.5 57.4 73.2 69.3 77.0 79.3 75.2 83.3 74.9 66.2 83.5 44.8 44.0 45.7
70-99 54.1 50.9 57.2 22.4 14.8 30.1 48.8 45.2 52.3 47.9 44.2 51.6 42.6 35.2 50.0 24.6 24.0 25.1
5 In Canada and Denmark we analysed patients diagnosed in 2004-7
Regional
Distant
Missing stage
1 Australia: New South Wales
2 Canada: Alberta and Manitoba
3 Sweden: Uppsala-Örebro and Stockholm-Gotland health regions
4 United Kingdom: Northern Ireland and all cancer registries in England
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NS (%) NS (%) NS (%) NS (%) NS (%) NS (%)
Dukes' stage
All ages 71.9 70.5 73.3 63.1 61.4 64.9 68.3 67.1 69.4 70.4 69.0 71.8 59.5 59.1 60.0
Age-standardised 71.1 70.0 72.1 62.4 61.2 63.7 68.8 68.0 69.6 70.7 69.6 71.7 59.9 59.5 60.2
15-49 79.4 76.1 82.6 72.0 66.7 77.3 78.0 75.0 81.1 74.3 70.0 78.6 69.7 68.3 71.0
50-69 76.6 74.8 78.3 72.5 70.4 74.5 74.9 73.5 76.3 76.2 74.5 77.9 67.8 67.2 68.3
70-99 65.8 63.6 68.0 53.7 51.1 56.2 62.4 60.8 64.1 65.8 63.7 67.9 52.5 51.9 53.1
All ages 94.0 91.5 96.4 94.8 91.0 98.6 96.4 94.9 97.9 97.1 95.5 98.7 94.0 93.2 94.8
Age-standardised 93.8 92.5 95.1 94.8 92.8 96.8 96.5 95.8 97.3 97.2 96.4 98.0 94.0 93.5 94.5
15-49 97.5 96.3 98.7 98.0 96.4 99.5 98.7 98.0 99.3 98.9 98.2 99.6 97.7 97.0 98.3
50-69 95.5 93.6 97.3 96.1 93.3 99.0 97.4 96.4 98.5 97.9 96.8 99.1 95.6 95.0 96.2
70-99 91.9 88.6 95.2 93.3 88.3 98.3 95.4 93.5 97.3 96.4 94.3 98.4 92.3 91.1 93.5
All ages 86.6 83.7 89.5 85.5 82.2 88.7 85.0 82.8 87.1 92.5 90.4 94.5 84.0 83.2 84.8
Age-standardised 86.1 84.2 88.0 84.9 82.8 87.0 85.8 84.6 87.1 92.5 91.3 93.7 84.1 83.6 84.6
15-49 96.1 93.7 98.6 94.7 91.5 97.9 96.2 94.7 97.7 93.0 89.7 96.3 91.9 90.9 93.0
50-69 91.2 88.5 93.8 89.4 86.3 92.5 91.1 89.4 92.8 92.6 90.8 94.4 87.2 86.4 88.0
70-99 80.7 75.7 85.7 80.7 75.8 85.6 80.0 76.7 83.2 92.3 89.3 95.2 81.0 79.8 82.2
All ages 80.3 77.4 83.1 75.5 72.3 78.8 74.6 72.1 77.2 75.1 72.3 77.8 67.4 66.5 68.3
Age-standardised 79.5 77.2 81.7 74.4 71.8 76.9 75.3 73.5 77.1 76.0 74.1 77.9 67.5 66.8 68.2
15-49 87.1 81.6 92.7 80.6 71.5 89.7 87.7 82.9 92.4 87.9 81.8 93.9 75.8 73.4 78.2
50-69 83.0 79.7 86.3 81.6 78.1 85.1 80.6 77.9 83.4 82.4 79.5 85.3 72.7 71.6 73.7
70-99 75.2 70.4 79.9 67.0 61.6 72.5 67.9 64.0 71.9 67.4 63.2 71.7 61.1 59.8 62.5
All ages 24.4 21.1 27.8 18.4 15.2 21.5 18.6 16.6 20.7 20.3 17.8 22.8 14.2 13.3 15.0
Age-standardised 23.1 21.4 24.7 18.3 16.7 19.9 19.1 18.0 20.1 20.6 19.3 21.8 14.4 13.9 15.0
15-49 30.6 26.4 34.8 25.1 20.8 29.4 26.0 22.7 29.2 27.1 23.2 30.9 20.3 17.9 22.7
50-69 29.2 25.5 32.8 23.4 19.7 27.0 24.6 22.1 27.0 26.0 23.1 28.9 18.9 17.8 20.1
70-99 16.4 13.4 19.4 12.3 9.6 15.1 12.7 10.8 14.5 14.0 11.7 16.3 9.1 8.3 10.0
All ages 70.4 67.6 73.1 54.7 51.0 58.5 64.0 61.5 66.4 41.5 36.4 46.6 38.1 37.3 38.8
Age-standardised 70.4 68.4 72.4 58.3 55.8 60.9 65.0 63.3 66.7 47.5 43.5 51.4 40.7 40.1 41.2
15-49 87.0 81.5 92.4 85.0 74.8 95.2 85.3 79.3 91.3 52.6 24.1 81.0 63.2 60.6 65.8
50-69 82.2 79.0 85.3 74.6 70.1 79.2 79.2 76.2 82.2 61.0 52.2 69.8 52.4 51.3 53.6
70-99 59.7 55.6 63.7 42.7 37.9 47.4 51.8 48.4 55.1 36.6 30.9 42.3 29.1 28.2 30.0
All ages 72.1 71.2 73.0 72.2 70.8 73.7 63.6 61.9 65.4 68.2 67.1 69.3 70.1 68.7 71.5 59.6 59.2 60.1
Age-standardised 71.1 70.4 71.8 71.4 70.3 72.5 62.9 61.6 64.2 68.7 67.9 69.6 70.4 69.3 71.4 60.0 59.6 60.3
15-49 77.2 75.0 79.5 79.6 76.4 82.8 72.4 67.2 77.6 77.9 74.8 81.0 73.9 69.6 78.3 69.7 68.4 71.1
50-69 76.8 75.7 77.9 76.8 75.0 78.5 72.8 70.7 74.8 74.8 73.4 76.3 75.9 74.2 77.6 67.9 67.3 68.4
70-99 66.5 65.1 68.0 66.3 64.1 68.5 54.3 51.8 56.8 62.4 60.7 64.0 65.4 63.4 67.5 52.6 52.0 53.2
All patients
Dukes' stage A
Dukes' stage B
Dukes' stage C
Dukes' stage D
Missing stage
SEER Summary Stage 2000
All patients
95% CI
Web appendix table 4. All-ages, age-specific and age-standardised three-year net survival (%) by stage at diagnosis, age and country for rectal cancer patients diagnosed during 2000-2007
Australia1 Canada2,5 Denmark5 Norway Sweden3 UK4
95% CI 95% CI 95% CI 95% CI 95% CI
All ages 89.5 88.3 90.7 92.4 90.4 94.3 91.0 88.5 93.5 89.8 88.4 91.1 95.0 93.6 96.3 88.5 87.9 89.1
Age-standardised 89.2 88.4 89.9 92.1 90.8 93.4 90.7 89.2 92.3 90.4 89.6 91.2 95.0 94.2 95.8 88.6 88.2 88.9
15-49 96.7 95.7 97.7 98.4 97.3 99.6 97.7 96.0 99.4 97.8 97.0 98.6 95.6 93.7 97.6 94.8 94.2 95.5
50-69 92.8 91.8 93.8 95.6 94.0 97.2 94.2 92.1 96.4 94.3 93.3 95.3 95.2 94.0 96.3 91.1 90.6 91.6
70-99 85.4 83.4 87.4 88.3 84.9 91.7 87.2 83.4 91.1 85.9 83.8 88.0 94.7 92.7 96.7 85.9 85.0 86.8
All ages 77.8 76.3 79.3 78.7 76.0 81.3 74.8 71.7 77.9 74.6 72.4 76.8 75.1 72.4 77.8 67.3 66.5 68.2
Age-standardised 77.7 76.6 78.8 77.9 75.9 80.0 73.8 71.4 76.2 75.6 74.1 77.2 76.0 74.1 77.9 67.4 66.8 68.1
15-49 82.3 79.0 85.5 85.8 80.3 91.4 79.8 70.9 88.6 86.5 81.7 91.3 87.5 81.3 93.7 75.2 72.8 77.6
50-69 81.9 80.2 83.5 81.6 78.4 84.8 80.7 77.3 84.0 81.8 79.4 84.2 82.4 79.5 85.2 72.6 71.6 73.6
70-99 72.5 70.0 75.0 73.3 68.8 77.8 66.7 61.6 71.9 67.5 64.1 70.9 67.4 63.2 71.7 61.2 59.8 62.5
All ages 23.6 21.6 25.6 24.5 21.2 27.8 18.4 15.2 21.6 18.2 16.3 20.0 20.3 17.8 22.8 14.2 13.4 15.0
Age-standardised 22.9 21.8 24.0 23.2 21.5 24.8 18.5 16.9 20.0 18.7 17.7 19.7 20.6 19.4 21.9 14.5 14.0 15.0
15-49 30.8 27.6 34.0 31.6 27.5 35.8 26.2 22.0 30.5 26.5 23.5 29.5 28.4 24.7 32.1 21.4 19.1 23.7
50-69 28.5 26.2 30.8 29.0 25.4 32.7 23.3 19.6 26.9 23.8 21.6 26.1 25.9 23.0 28.7 18.8 17.7 19.9
70-99 16.1 14.2 18.1 16.4 13.3 19.4 12.4 9.6 15.1 12.1 10.5 13.8 14.0 11.7 16.3 9.1 8.3 9.9
All ages 69.0 66.4 71.7 69.2 66.4 72.1 54.6 50.9 58.3 47.0 42.2 51.8 41.4 36.2 46.5 38.0 37.3 38.8
Age-standardised 66.8 64.7 69.0 68.8 66.7 70.9 57.5 54.9 60.1 55.9 52.4 59.4 47.0 43.1 50.9 40.1 39.5 40.6
15-49 88.6 83.7 93.6 86.4 80.8 92.0 85.1 75.0 95.2 84.1 70.8 97.4 52.8 24.2 81.3 63.2 60.6 65.9
50-69 80.5 77.2 83.8 81.2 78.0 84.5 74.6 70.1 79.2 78.3 71.3 85.2 61.0 52.2 69.8 52.5 51.3 53.6
70-99 56.4 52.3 60.6 58.4 54.2 62.5 42.5 37.7 47.2 32.2 26.5 38.0 36.5 30.8 42.2 29.0 28.1 29.9
1 Australia: New South Wales
2 Canada: Alberta, British Columbia and Manitoba
3 Sweden: Uppsala-Örebro and Stockholm-Gotland health regions
4 United Kingdom: Northern Ireland and all cancer registries in England except the Thames Cancer Registry
5 In Canada and Denmark we analysed patients diagnosed in 2004-7
Missing stage
Localised
Regional
Distant
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